Literature DB >> 19954473

Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.

Katsuichi Miyamoto1, Susumu Kusunoki.   

Abstract

Neuromyelitis optica (NMO) is a relapsing inflammatory condition characterized by selective involvement of the optic nerves and spinal cord. Humoral immune mechanisms play a role in the pathogenesis of NMO. The therapeutic efficacy of plasmapheresis (PP) has been reported in the cases that were poorly controlled with other treatments. Herein, we report four patients with NMO who underwent PP following intensive intravenous corticosteroid therapy. All patients showed definite functional improvement following one to five plasma exchanges. To prevent relapse, these patients were treated with oral prednisolone in combination with azathioprine or cyclophosphamide. Two of the four patients also underwent intermittent PP because treatment with oral agents was unsuccessful. In conclusion, when treatment with oral immunosuppressants is ineffective in reducing recurrences of NMO, an additional PP session should be attempted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19954473     DOI: 10.1111/j.1744-9987.2009.00780.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  25 in total

1.  Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain.

Authors:  Samira Saadoun; Patrick Waters; Claire MacDonald; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Ann Neurol       Date:  2012-02-28       Impact factor: 10.422

2.  Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.

Authors:  Hua Zhang; Jeffrey L Bennett; A S Verkman
Journal:  Ann Neurol       Date:  2011-11-08       Impact factor: 10.422

Review 3.  Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.

Authors:  Nicolas Collongues; Laure Michel; Jérôme de Seze
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 4.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

5.  Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays.

Authors:  Puay-Wah Phuan; Julien Ratelade; Andrea Rossi; Lukmanee Tradtrantip; A S Verkman
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

6.  [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Authors:  C Trebst; A Berthele; S Jarius; T Kümpfel; S Schippling; B Wildemann; C Wilke
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

7.  Current and future treatment approaches for neuromyelitis optica.

Authors:  Nicolas Collongues; Jérôme de Seze
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

Review 8.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Immunoadsorption in patients with neuromyelitis optica spectrum disorder.

Authors:  Simon Faissner; Johanna Nikolayczik; Andrew Chan; Ralf Gold; Min-Suk Yoon; Aiden Haghikia
Journal:  Ther Adv Neurol Disord       Date:  2016-05-15       Impact factor: 6.570

10.  Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.

Authors:  Hua Zhang; A S Verkman
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.